Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24054476 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Timothy M Panknin und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Arizona, Tucson, AZ 85724, USA. Hauptthemen laut MEDLINE: Curcumin, Osteoarthritis. Die Arbeit wurde bisher 115-mal zitiert (Crossref) und nennt 431 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Medicinal properties of turmeric (Curcuma longa L.), a plant used for centuries as an anti-inflammatory, are attributed to its polyphenolic curcuminoids, where curcumin predominates. Although “curcumin” supplements are a top-selling botanical with promising pre-clinical effects, questions remain regarding biological activity in humans. To address this, a scoping review was conducted to assess human clinical trials reporting oral curcumin effects on disease outcomes. Eight databases were searched using established guidelines, yielding 389 citations (from 9528 initial) that met inclusion criteria. Half focused on obesity-associated metabolic disorders (29%) or musculoskeletal disorders (17%), where inflammation is a key driver, and beneficial effects on clinical outcomes and/or biomarkers were reported for most citations (75%) in studies that were primarily double-blind, randomized, and placebo-controlled trials (77%, D-RCT). Citations for the next most studied disease categories (neurocognitive [11%] or gastrointestinal disorders [10%], or cancer [9%]), were far fewer in number and yielded mixed results depending on study quality and condition studied. Although additional research is needed, including systematic evaluation of diverse curcumin formulations and doses in larger D-RCT studies, the preponderance of current evidence for several highly studied diseases (e.g., metabolic syndrome, osteoarthritis), which are also clinically common, are suggestive of clinical benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
- The University of Arizona Health Science Library, Tucson, AZ 85724, USA.
- University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
- Department of Physiology, Honors College, University of Arizona, Tucson, AZ 85724, USA.
- Department of Medicine and School of Nutritional Sciences and Wellness, University of Arizona, Tucson, AZ 85724, USA.
Förderung
- NIAMS NIH HHS
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Panknin, T. M., Howe, C. L., Hauer, M., Bucchireddigari, B., Rossi, A. M., & Funk, J. L. (2023). Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054476
Vancouver
Panknin TM, Howe CL, Hauer M, Bucchireddigari B, Rossi AM, Funk JL. Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054476
BibTeX
@article{Panknin2023,
author = {Panknin, Timothy M and Howe, Carol L and Hauer, Meg and Bucchireddigari, Bhanu and Rossi, Anthony M and Funk, Janet L},
title = {Curcumin Supplementation and Human Disease: A Scoping Review of Clinical Trials},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24054476}
}
EUVIMED